In a move that signals a significant shift in the relationship between Big Pharma and the federal government, Johnson & Johnson (NYSE: JNJ) announced a [Read More…]
Eli Lilly expands its clinical-stage portfolio with the $1.2 billion acquisition of Ventyx Biosciences, securing high-potential oral NLRP3 inhibitors to treat chronic inflammation and neurodegenerative disorders.
GSK plc (LSE/NYSE: GSK) today announced positive results from its pivotal Phase III clinical trial program for bepirovirsen. This investigational treatment could redefine the standard [Read More…]
In its first major move of 2026, Amgen (NASDAQ: AMGN) has announced the acquisition of Dark Blue Therapeutics Ltd., a privately held U.K. biotech specializing [Read More…]
Novo Nordisk has officially launched the Wegovy® pill, the first-ever oral GLP-1 medication for weight management in adults. Following FDA approval in late 2025, this once-daily pill offers a needle-free alternative to injections, demonstrating an average weight loss of up to 17% in clinical trials. With tiered pricing starting at $149 per month for self-pay patients, oral Wegovy is now available through major U.S. pharmacies and select telehealth platforms.
In a significant legal victory, Novo Nordisk announced on December 31, 2025, that China’s Supreme People’s Court had issued a final, positive ruling upholding the [Read More…]
Johnson & Johnson has finalized a landmark $3.05 billion acquisition of Halda Therapeutics, integrating the clinical-stage biotech’s proprietary RIPTAC™ platform. This strategic move adds HLD-0915—a next-generation oral therapy for prostate cancer to J&J’s portfolio, signaling a major shift toward precision, “cell-killing” mechanisms designed to overcome traditional treatment resistance.
If 2024 was the year of “hype” for AI and GLP-1s, 2025 became the year of clinical delivery. We moved beyond the theoretical promise of [Read More…]
The FDA has officially approved the first-ever oral version of Wegovy, a once-daily tablet from Novo Nordisk. With clinical trials showing a 16.6% average weight loss, this landmark approval offers a needle-free alternative for obesity management and cardiovascular protection starting in January 2026.
The FDA has granted accelerated approval to Roche’s Lunsumio VELO™, a revolutionary subcutaneous formulation for adult patients with relapsed or refractory follicular lymphoma. By reducing administration time from several hours to just one minute, this CD20xCD3 bispecific antibody offers a more flexible, outpatient-friendly treatment option. Supported by a 75% objective response rate in heavily pre-treated patients, Lunsumio VELO marks a major shift toward patient-centered oncology care in 2025.
